By proceeding, you agree to our Terms of Use and Privacy Policy.
We are a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for refractive and retina disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting significant unmet needs.
27-27 July 2023
Welcome to OIS Retina 2023, the leading gathering of clinical, corporate, and capital leaders dedicated to advancing novel technologies and addressing the most significant unmet medical needs in the field of retina. This highly anticipated event brin
Event Ended
USA
Paid
Seattle